Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion
Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion
Not yet recruiting · NCT07482605 · Registry updated 2026-07-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion | Neoplasms by Histologic Type, Neoplasms by Site, Pleural Effusion, Pleural Effusion, Malignant, Thoracic Neoplasms, adenocarcinoma, bronchial neoplasm, bronchogenic carcinoma, carcinoma, epithelial neoplasm, lung adenocarcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, pleural disorder, pleural neoplasm, respiratory system disorder, respiratory tract neoplasm | Not yet recruiting | Phase 2 | 2026-07-17 | NCT07482605 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Jiangmen Central Hospital | 27 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||